|A randomized controlled clinical trial of palliative therapies for patients with inoperable esophageal cancer.|
|PMID: 19436289 Owner: NLM Status: MEDLINE|
|OBJECTIVES: A dramatic rise in incidence, an aging population, and expensive palliative treatments have led to an escalating burden on clinicians managing inoperable esophageal cancer with only limited evidence of effectiveness. This study compares the clinical effectiveness and cost-effectiveness of self-expanding metal stents (SEMSs) with other palliative therapies to aid clinicians in making an evidence-based treatment choice.
METHODS: We conducted a prospective, multicenter, randomized, controlled, clinical trial with 215 patients followed until death or study closure. The primary outcome measures were dysphagia, quality of life (QL) 6 weeks following treatment, and total cost of treatment. Secondary outcome measures included treatment-associated morbidity, mortality, survival, and cost-effectiveness. An intention-to-treat analysis was carried out.
RESULTS: There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment (P=0.046), with worse swallowing reported by rigid stent-treated patients (mean dysphagia score difference=-0.49; 95% confidence interval (CI) -0.10 to -0.89, P=0.014). Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs (mean difference QL index week 1=-0.66; 95% CI: -0.02 to -1.30, P=0.04; mean difference QL index week 6=-1.01; 95% CI -0.30 to -1.72, P=0.006). These findings were associated with higher post-procedure pain scores in the SEMS patient group (mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1=11.13; 95% CI: 2.89-19.4; P=0.01). Although mean EQ-5D QL values differed between the treatments (P<0.001), this difference dissipated following generation of quality-adjusted life year values. Total costs varied between treatment arms but these findings canceled out when SEMSs were compared with non-SEMS therapies (95% CI -845.15-1,332.62). These results were robust to sensitivity analysis. There were no differences in the in-hospital mortality or early complication rates, but late complications were more frequent after rigid stenting (risk ratio=2.47; 95% CI 1.88-3.04). There was a survival advantage for non-stent-treated patients (log-rank statistic=4.21, P=0.04).
CONCLUSIONS: The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences.
|Jonathan Shenfine; Paul McNamee; Nick Steen; John Bond; S Michael Griffin|
Related Documents :
|16571959 - Prognosis value of plasma s100b protein levels after subarachnoid aneurysmal hemorrhage.
22328889 - Mycophenolate mofetil (mmf) treatment efficacy in children with primary and secondary g...
22772459 - Usefulness of ultrasonography-proven tenosynovitis to monitor disease activity of a pat...
17591479 - Time-limited fluoroscopy to reduce radiation exposure during ercp: a prospective random...
12945019 - Effect of postoperative epidural analgesia on morbidity and mortality after total hip r...
16820609 - Perioperative increases in serum creatinine are predictive of increased 90-day mortalit...
24441759 - Aesthetic and sensory reconstruction of finger pulp defects using free toe flaps.
4019759 - Polydactyly of the foot.
9425969 - A low-dose hypobaric bupivacaine spinal anesthesia for knee arthroscopies.
|Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2009-05-12|
|Title: The American journal of gastroenterology Volume: 104 ISSN: 1572-0241 ISO Abbreviation: Am. J. Gastroenterol. Publication Date: 2009 Jul|
|Created Date: 2009-07-03 Completed Date: 2009-07-24 Revised Date: 2011-01-26|
Medline Journal Info:
|Nlm Unique ID: 0421030 Medline TA: Am J Gastroenterol Country: United States|
|Languages: eng Pagination: 1674-85 Citation Subset: IM|
|Northern Oesophago-Gastric Cancer Unit, Royal Victoria Infirmary, Newcastle Upon Tyne, UK.|
|APA/MLA Format Download EndNote Download BibTex|
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Balloon Dilation / instrumentation
Cause of Death
Critical Illness / therapy
Deglutition Disorders / etiology, therapy*
Esophageal Neoplasms / complications, mortality*, pathology, therapy*
Neoplasm Invasiveness / pathology
Palliative Care / methods*
Quality of Life*
Severity of Illness Index
|Ann Surg Oncol. 2011 Jan;18(1):286; author reply 287-8
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pancreatic ductal abnormalities documented by secretin-enhanced MRCP in asymptomatic subjects with c...
Next Document: C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer b...